-
DiscoveryTackling the common denominator in liver disease
Researchers focus on reversing the scarring that’s common to liver diseases.
Discovery -
DiscoveryCancer researchers ready to aim for cures
New head of oncology research hopes to build on recent advances, explore new therapeutic approaches and beat certain cancers for good.
Discovery -
DiscoveryConfidence led this researcher to swim against the current
A researcher reflects on her successful journey from Venezuela to the US in which she became a doctor, a scientist, and a mother.
Discovery -
DiscoveryThe eye: the fastest muscle in the human body
How much do you know about eyes? Learn more about the fastest muscle in the human body.
Discovery -
DiscoveryCollaborating to unlock secrets of the microbiome
Novartis and Broad Institute researchers explore how gut bacteria contribute to health and disease, beginning with type 1 diabetes.
Discovery -
DiscoveryTalking to: Bruno Strigini on why we're entering a transformative time in cancer care
Accelerating Research to Get Answers Faster
Discovery -
DiscoveryFactory foreman keeps liver’s line workers on task
A complex protein module keeps the liver’s biochemical factory running smoothly and at capacity.
Discovery -
DiscoveryHow scientists aim to expand immunotherapy options for cancer patients
Read how NIBR and Dana-Farber scientists aim to expand immunotherapy options for patients
Discovery -
DiscoveryIntractable tumor cells crippled
Functional genomics study reveals a potential approach for tackling glioblastoma, pancreatic cancer and other tumors.
Discovery -
DiscoveryLeveraging the liver’s ability to heal scarred tissue
A reversal in thinking about the reversibility of liver damage is changing the field of hepatology.
Discovery -
DiscoveryNeuroscientists restore cell-to-cell signaling and sociability in autism models
Team uncovers a potential therapeutic approach for patients deficient in a protein called Shank3.
Discovery -
DiscoveryNovartis and Pfizer join forces to upend oncology dogma
Industry labs find that, contrary to earlier evidence, KRAS-driven tumors are not addicted to autophagy.
Discovery